BGI

Shenzhen, China
Shenzhen, China
SEARCH FILTERS
Time filter
Source Type

News Article | April 20, 2017
Site: marketersmedia.com

— This report studies DNA Sequencing in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Illumina Roche Macrogen BGI WuXi AppTec DAAN GENE Novo Gene Berry Genomics Biomarker Majorbio CapitalBio Genomics Anoroad King Med Didan Diagostics ZiXin Da Rui Adicon For more information or any query mail at sales@wiseguyreports.com By types, the market can be split into First Generation DNA Sequencing Second Generation DNA Sequencing Third Generation DNA Sequencing By Application, the market can be split into Oncology DNA Sequencing Life Science DNA Sequencing Emerging Application DNA Sequencing Hereditary Disease Detection DNA Sequencing By Regions, this report covers (we can add the regions/countries as you want) North America China Europe Southeast Asia Japan India Global DNA Sequencing Market Professional Survey Report 2017 1 Industry Overview of DNA Sequencing 1.1 Definition and Specifications of DNA Sequencing 1.1.1 Definition of DNA Sequencing 1.1.2 Specifications of DNA Sequencing 1.2 Classification of DNA Sequencing 1.2.1 First Generation DNA Sequencing 1.2.2 Second Generation DNA Sequencing 1.2.3 Third Generation DNA Sequencing 1.3 Applications of DNA Sequencing 1.3.1 Oncology DNA Sequencing 1.3.2 Life Science DNA Sequencing 1.3.3 Emerging Application DNA Sequencing 1.3.4 Hereditary Disease Detection DNA Sequencing 1.4 Market Segment by Regions 1.4.1 North America 1.4.2 China 1.4.3 Europe 1.4.4 Southeast Asia 1.4.5 Japan 1.4.6 India 2 Manufacturing Cost Structure Analysis of DNA Sequencing 2.1 Raw Material and Suppliers 2.2 Manufacturing Cost Structure Analysis of DNA Sequencing 2.3 Manufacturing Process Analysis of DNA Sequencing 2.4 Industry Chain Structure of DNA Sequencing 3 Technical Data and Manufacturing Plants Analysis of DNA Sequencing 3.1 Capacity and Commercial Production Date of Global DNA Sequencing Major Manufacturers in 2016 3.2 Manufacturing Plants Distribution of Global DNA Sequencing Major Manufacturers in 2016 3.3 R&D Status and Technology Source of Global DNA Sequencing Major Manufacturers in 2016 3.4 Raw Materials Sources Analysis of Global DNA Sequencing Major Manufacturers in 2016 8 Major Manufacturers Analysis of DNA Sequencing 8.1 Illumina 8.1.1 Company Profile 8.1.2 Product Picture and Specifications 8.1.2.1 Product A 8.1.2.2 Product B 8.1.3 Illumina 2016 DNA Sequencing Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.1.4 Illumina 2016 DNA Sequencing Business Region Distribution Analysis 8.2 Roche 8.2.1 Company Profile 8.2.2 Product Picture and Specifications 8.2.2.1 Product A 8.2.2.2 Product B 8.2.3 Roche 2016 DNA Sequencing Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.2.4 Roche 2016 DNA Sequencing Business Region Distribution Analysis 8.3 Macrogen 8.3.1 Company Profile 8.3.2 Product Picture and Specifications 8.3.2.1 Product A 8.3.2.2 Product B 8.3.3 Macrogen 2016 DNA Sequencing Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.3.4 Macrogen 2016 DNA Sequencing Business Region Distribution Analysis 8.4 BGI 8.4.1 Company Profile 8.4.2 Product Picture and Specifications 8.4.2.1 Product A 8.4.2.2 Product B 8.4.3 BGI 2016 DNA Sequencing Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.4.4 BGI 2016 DNA Sequencing Business Region Distribution Analysis 8.5 WuXi AppTec 8.5.1 Company Profile 8.5.2 Product Picture and Specifications 8.5.2.1 Product A 8.5.2.2 Product B 8.5.3 WuXi AppTec 2016 DNA Sequencing Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.5.4 WuXi AppTec 2016 DNA Sequencing Business Region Distribution Analysis 8.6 DAAN GENE 8.6.1 Company Profile 8.6.2 Product Picture and Specifications 8.6.2.1 Product A 8.6.2.2 Product B 8.6.3 DAAN GENE 2016 DNA Sequencing Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.6.4 DAAN GENE 2016 DNA Sequencing Business Region Distribution Analysis 8.7 Novo Gene 8.7.1 Company Profile 8.7.2 Product Picture and Specifications 8.7.2.1 Product A 8.7.2.2 Product B 8.7.3 Novo Gene 2016 DNA Sequencing Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.7.4 Novo Gene 2016 DNA Sequencing Business Region Distribution Analysis 8.8 Berry Genomics 8.8.1 Company Profile 8.8.2 Product Picture and Specifications 8.8.2.1 Product A 8.8.2.2 Product B 8.8.3 Berry Genomics 2016 DNA Sequencing Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.8.4 Berry Genomics 2016 DNA Sequencing Business Region Distribution Analysis 8.9 Biomarker 8.9.1 Company Profile 8.9.2 Product Picture and Specifications 8.9.2.1 Product A 8.9.2.2 Product B 8.9.3 Biomarker 2016 DNA Sequencing Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.9.4 Biomarker 2016 DNA Sequencing Business Region Distribution Analysis 8.10 Majorbio 8.10.1 Company Profile 8.10.2 Product Picture and Specifications 8.10.2.1 Product A 8.10.2.2 Product B 8.10.3 Majorbio 2016 DNA Sequencing Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.10.4 Majorbio 2016 DNA Sequencing Business Region Distribution Analysis 8.11 CapitalBio Genomics 8.12 Anoroad 8.13 King Med 8.14 Didan Diagostics 8.15 ZiXin 8.16 Da Rui 8.17 Adicon For more information or any query mail at sales@wiseguyreports.com ABOUT US: Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of rmaket research reports under these categories and sub-categories. For more information, please visit https://www.wiseguyreports.com


News Article | April 17, 2017
Site: www.eurekalert.org

Today (April 12), UC Davis researchers announced in Nature Communications that they have unlocked a treasure-trove of genetic information about lettuce and related plants, releasing the first comprehensive genome assembly for lettuce and the huge Compositae plant family. Garden lettuce, or Lactuca sativa, is the plant species that includes a salad bar's worth of lettuce types, ranging from iceberg to romaine. With an annual on-farm value of more than $2.4 billion, it is the most valuable fresh vegetable and one of the 10 most valuable crops, overall, in the United States. Lettuce is a member of the huge Compositae family, which includes the good, the bad, and the ugly of the plant world, from the daisy and sunflower to ragweed and the dreaded star thistle. The genome assembly -- a compilation of millions of DNA sequences into a useful genetic portrait -- provides researchers with a valuable tool for exploring the Compositae family's many related plant species. "This genome assembly provides the foundation for numerous further genetic, evolutionary and functional studies of this whole family of plants," said Sebastian Reyes-Chin-Wo, the lead author and a graduate student in the laboratory of plant geneticist Richard Michelmore. "This is particularly significant because Compositae is the most successful family of flowering plants on earth in terms of the number of species and environments inhabited," said Richard Michelmore, who directs the UC Davis Genome Center. The researchers found that specific genes in the lettuce genome were consistent with certain physical traits -- like the production of a rubber-containing milky sap -- that have also been found in taxonomically distinct species, such as the rubber tree. The study also provided evidence that somewhere during the evolution of lettuce about 45 million years ago, its genome was "triplicated." As a result, one-fourth of the genome -- including about 30 percent of all of its identified genes -- now appears in multiple related regions. Because such genomic duplications may give plant species an advantage in colonizing new environments, the ancient triplication event might, in part, explain the success of the Compositae plant family. Michelmore noted that this is the first reported genome assembly of a plant species resulting from use of a new technology that gives information about the physical proximity of the DNA sequences to which proteins are bound. The new approach, developed by Dovetail Genomics, a company spun out from UC Santa Cruz, resulted in a more contiguous and accurate genome assembly, even though lettuce has one of the larger plant genomes sequenced to date, he said. The sequencing was done in collaboration with the genomics firm BGI. Funding was provided by 10 plant breeding companies through the Lettuce Genomics Sequencing Consortium, UC Davis Genome Center, National Science Foundation and U.S. Department of Agriculture.


News Article | May 1, 2017
Site: www.biosciencetechnology.com

Digital imaging is another area where HPC-enabled speedups are advancing clinical care. Panelist Simon K. Warfield described innovative imaging techniques his team is applying to increase understanding of the brain’s complex circuitry. Dr. Warfield is the Thorne Griscom Professor of Radiology at Harvard Medical School and the founder and director of the Computational Radiology Lab (CRL) at Boston Children's Hospital. CRL is an Intel Parallel Computing Center that is modernizing the algorithms and data structures of medical image computing on Intel Xeon and Intel Xeon Phi processors. The lab is improving cache performance, vectorization performance and multi-threading performance, as well as creating more sophisticated imaging and modeling strategies. CRL can contribute to improved diagnosis and treatment of brain injuries, multiple sclerosis, depression, Alzheimer’s and many other conditions. Consider the novel technique CRL has developed to show more clearly water’s diffusion through the brain—and pinpoint hindrances and restrictions to its flow. In contrast to traditional image processing approaches, CRL’s diffusion-weighted imaging infers new parametric maps from data measurements. Its computational model includes tens or hundreds of 3D images—each up to 10 million pixels each—as its inputs. “This type of analysis is very computationally intensive,” Warfield said. “With the accelerated algorithm and the Intel Xeon Phi processors, we reduced the time needed from 48 hours to 15 minutes of calculations.” That speedup can translate to immediate benefits in for critically ill patients facing brain surgery. That’s because, as Warfield put it, “When you’re talking about surgical planning, life is a matter of time.” Recently, one of the hospital’s neurosurgery teams realized on a Friday that their patient’s conventional magnetic resonance scan was not clear enough to allow them to proceed with a planned brain resection. With the surgery-planning meeting scheduled for Monday, they requested emergency use of CRL’s diffusion imaging algorithm. The patient had a new scan Saturday evening, the data was processed on Sunday, and the information was ready for the team’s decision on Monday. The panel also highlighted precision medicine’s global reach—and its big data challenges. Fang Lin, Director of the Bioinformatics Center at BGI, described BGI’s use of the Lustre file system to help maintain storage performance as its data volumes grow. BGI is a global research leader as well as a provider of genetic testing products. It also operates the China National Genebank, putting it on the forefront of China’s five-year. BGI cranks 20 terabytes of sequencing data every day. The institute stores13petabytes of genomic data and uses a 10 petabyte file system comprising Intel Enterprise Edition for Lustre Software and open source technologies. Dr. David Torrents, a molecular biologist and research professor at the Barcelona Supercomputing Center, shone a spotlight on the importance of collaboration in advancing precision medicine. BSC provides resources to a variety of international centers and consortia. In addition, the institute conducts its own multidisciplinary research in computational biomedicine and related fields. BSC’s alliances also encompass a range of hospitals and medical centers, enabling it to validate and test its models and tools with data from clinical institutions. “We’re at an exciting moment,” Torrents said. “We are not just developing new solutions for personalized medicine, but now are beginning a pilot program in January 2017 to bring them together and apply them in clinical settings, beginning in Catalonia and then throughout Spain.” The panelists say continued leaps forward in precision medicine will come from faster and more sophisticated analysis of larger volumes of more varied data types. “What we want is a more holistic picture, and for that, it’s becoming absolutely critical to combine many diverse data types together for analysis,” said Lowey. To achieve that holistic picture, researchers want to use deep learning and other forms of artificial intelligence. They also want to apply those AI methods to genomic data in combination with imaging data, lifelong clinical records, population studies, environmental studies, and much more. Different aspects of the precision medicine workflow will have varying processing and storage requirements. So the push continues for faster performance with agile or heterogeneous platform architectures rather than a single “silver bullet” approach. The processors will continue as the primary workhorses, supplemented by embedded resources and FPGA accelerators for parts of the workflow. Distributed compute and storage resources will remain crucial, along with advances in applications and tools. As to the clinical impact of these holistic approaches, look no further than Boston Children’s Hospital. Noninvasive prenatal genomic testing can indicate whether a fetus has the risk factors that predispose it to be born with a malformed heart. If genetic testing shows these factors are present, data-intensive digital imaging can reveal whether the heart is actually deformed. By combining genomic with other medical data in this way, clinicians can provide peace of mind for worried parents-to-be, or help them plan for their child’s future. “We’re starting to connect the genetics that predisposes an individual to heart disease, with the imaging to see if the defect is present, and use that information to influence current treatment,” said Warfield. “That information can also help us plan for the child’s longer-term future. We can predict how they’ll do as teenagers and begin to plan accordingly.” Precision medicine is one of the most promising and meaningful applications of high-performance computing today. “It’s still early days, but we’re moving toward an exciting new era of predictive biology and personalized medicine,” said McManus. “Our panelists gave us a great taste of what’s on the horizon. With continued advances in platform technologies, artificial intelligence, and other areas, we create significant opportunities to increase the science of medicine and ultimately improve human health. Intel is excited to empower scientists and clinicians with technology innovations, resources and expertise as we collaborate to make this new era a reality.” Jan Rowell writes about technology trends in HPC, healthcare, life sciences, and other industries.


"As one of the world's largest genome centers, we are delighted to see users in China and around the world get access to state-of-the-art genome analysis tools through the BGI Online platform," said Xin Jin, Deputy Director of Research and Development Center at BGI and director of the BGI Online platform. "We are processing millions of samples each year through BGISEQ-500 sequencers. By providing the cloud-based solution, we can greatly expand access and accelerate both scientific research and clinical applications with cutting-edge genomics technology." "In our global effort to drive breakthroughs in human health, high-quality data is paramount," said Eric Banks, Senior Director of Data Sciences and Data Engineering at the Broad Institute. "We want to help ensure that every researcher, scientist, and analyst has access to the best genomic analysis tools. We are pleased that GATK best practices will be used in the BGI Online platform." "BGI Online offering the newest version of GATK, including optimizations developed through Intel's collaboration with the Broad Institute, means two of the world's top genomics centers will use common open source tools," said Jason Waxman, corporate vice president of the Intel Data Center Solutions Group. "This is a big step toward making state-of-the-art genomic data analysis available worldwide." "As one of the world's leading cloud computing company, Alibaba Cloud looks forward to leveraging our data intelligence and computing power, and accelerating the development of bioinformatics. We are excited to be part of this collative effort in bringing GATK4 to Chinese users and making genome analysis technology more inclusive," said Jin Li, Senior Director at Alibaba Cloud. About BGI Online BGI Online is a powerful and secure cloud platform for genomics data analysis. The platform exploits the powerful computing and unlimited storage capabilities of Amazon Web Services and Alibaba Cloud. BGI Online provides easier and more effective solutions to institutions from data storage, automated analysis, and data delivery to project partnership and bioinformatics methods development. For more information please visit www.bgionline.com (Global) and www.bgionline.cn (China). To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bgi-to-work-with-broad-institute-intel-and-alibaba-cloud-to-provide-free-access-to-gatk4-on-bgi-online-platform-300463295.html


News Article | May 26, 2017
Site: www.prnewswire.co.uk

Browse 42 market data tables and 45 figures spread through 153 pages and in-depth TOC on "NGS-based RNA-seq Market" Early buyers will receive 10% customization on this report. NGS-based RNA-seq Market Report provides a detailed overview of the major drivers, restraints, and threat impacting the high-resolution melting analysis market along with the estimates and forecasts of the revenue and market share analysis. Factors such as the advantages of RNA-seq over microarray technology, technological advancements in RNA-seq products, increasing number of RNA-seq grants, increasing number of research activities, and rapid growth in precision medicine are driving the growth of the market. On the basis of product and service, the NGS-based RNA-seq market is categorized into sample preparation, sequencing platforms and consumables, sequencing services, and data analysis, storage, & management. In 2016, the sequencing platforms and consumables segment accounted for the largest share of the market. The data analysis, storage, and management is expected to register the highest CAGR during the forecast period primarily due to development of more efficient data analysis solutions and growing computational capabilities of data analytics providers. On the basis of technology, the market is segmented into sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing. In 2016, the SBS technology accounted for the largest share of the market, majorly due to the development of new and advanced NGS platforms, the increasing demand for Illumina's systems (including the HiSeq and MiSeq series) and the growing demand for NextSeq and HiSeq X Ten for RNA & DNA sequencing. Based on applications, the market is categorized into four segments, namely, de novo transcriptome assembly, expression profiling analysis, variant calling & transcriptome epigenetics, and small RNA sequencing. The expression profiling analysis segment accounted for the major share of the global NGS-based RNA-Seq market. On the basis of end user, the market is segmented into research centers and academic & government institutes, hospitals & clinics, pharmaceutical & biotechnology companies, and other end users. The research centers and academic & government institutes segment accounted for the largest share of the market in 2016 owing to the growing number of government funding programs and the increasing focus of market players on providing efficient RNA-seq products and services for research applications. Among these end users, the hospitals and clinics segment is expected to register the highest CAGR due to the growing number of agreements between companies and hospitals for the development of advanced tests and products catering to the specific needs of hospitals and clinics. Geographically, the NGS-based RNA-seq market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest share of the market in 2016, followed by Europe. The market in North America is primarily driven by government support through funds for genomics research, advancements in RNA-seq products, growing prevalence of target diseases, growing research on cancer and inherited rare diseases, and the strong presence of key players in this region. However, Asia-Pacific is expected to register the highest growth rate during the forecast period from 2017 to 2022, due to the significant focus on R&D activities as a means of broadening the scope of RNA-seq applications and decreasing the costs of NGS products & services in this region. The major players of the NGS-based RNA-seq market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N. V. (Germany), Pacific Biosciences of California, Inc. (U.S.), BGI (China), Oxford Nanopore Technologies, Ltd. (U.K.), PerkinElmer, Inc. (U.S.), GATC Biotech AG (Germany), Agilent Technologies, Inc. (U.S.), Roche Holding AG (Switzerland), Macrogen, Inc. (South Korea), and Eurofins Scientific (Luxembourg). The market is characterized by high competition and innovative product launches. Oxford Nanopore Technologies (U.K.) is a strong emerging market player with strong innovative solutions based on nanopore sequencing technology. For instance, in December 2016, Oxford Nanopore Technologies introduced its direct RNA sequencing kits to a small number of researchers. Additionally, in June 2014, F. Hoffmann-La Roche AG acquired Genia Technologies, Inc. (U.S.), to enhance its sequencing platform capabilities using nanopore technology. Next-Generation Sequencing (NGS) Market by Product (Hiseq, Miseq, Hiseq X Ten/X Five, NextSeq500, Ion Proton, PGM, Ions5, PacBio RSII), Services (Targeted, RNA, Exome, De Novo), & Application (Diagnostics, Biomarker, Agriculture) - Global Forecasts to  022 http://www.marketsandmarkets.com/Market-Reports/next-generation-sequencing-ngs-technologies-market-546.html MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets


News Article | May 26, 2017
Site: www.prnewswire.com

Browse 42 market data tables and 45 figures spread through 153 pages and in-depth TOC on "NGS-based RNA-seq Market" Early buyers will receive 10% customization on this report. NGS-based RNA-seq Market Report provides a detailed overview of the major drivers, restraints, and threat impacting the high-resolution melting analysis market along with the estimates and forecasts of the revenue and market share analysis. Factors such as the advantages of RNA-seq over microarray technology, technological advancements in RNA-seq products, increasing number of RNA-seq grants, increasing number of research activities, and rapid growth in precision medicine are driving the growth of the market. On the basis of product and service, the NGS-based RNA-seq market is categorized into sample preparation, sequencing platforms and consumables, sequencing services, and data analysis, storage, & management. In 2016, the sequencing platforms and consumables segment accounted for the largest share of the market. The data analysis, storage, and management is expected to register the highest CAGR during the forecast period primarily due to development of more efficient data analysis solutions and growing computational capabilities of data analytics providers. On the basis of technology, the market is segmented into sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing. In 2016, the SBS technology accounted for the largest share of the market, majorly due to the development of new and advanced NGS platforms, the increasing demand for Illumina's systems (including the HiSeq and MiSeq series) and the growing demand for NextSeq and HiSeq X Ten for RNA & DNA sequencing. Based on applications, the market is categorized into four segments, namely, de novo transcriptome assembly, expression profiling analysis, variant calling & transcriptome epigenetics, and small RNA sequencing. The expression profiling analysis segment accounted for the major share of the global NGS-based RNA-Seq market. On the basis of end user, the market is segmented into research centers and academic & government institutes, hospitals & clinics, pharmaceutical & biotechnology companies, and other end users. The research centers and academic & government institutes segment accounted for the largest share of the market in 2016 owing to the growing number of government funding programs and the increasing focus of market players on providing efficient RNA-seq products and services for research applications. Among these end users, the hospitals and clinics segment is expected to register the highest CAGR due to the growing number of agreements between companies and hospitals for the development of advanced tests and products catering to the specific needs of hospitals and clinics. Geographically, the NGS-based RNA-seq market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest share of the market in 2016, followed by Europe. The market in North America is primarily driven by government support through funds for genomics research, advancements in RNA-seq products, growing prevalence of target diseases, growing research on cancer and inherited rare diseases, and the strong presence of key players in this region. However, Asia-Pacific is expected to register the highest growth rate during the forecast period from 2017 to 2022, due to the significant focus on R&D activities as a means of broadening the scope of RNA-seq applications and decreasing the costs of NGS products & services in this region. The major players of the NGS-based RNA-seq market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N. V. (Germany), Pacific Biosciences of California, Inc. (U.S.), BGI (China), Oxford Nanopore Technologies, Ltd. (U.K.), PerkinElmer, Inc. (U.S.), GATC Biotech AG (Germany), Agilent Technologies, Inc. (U.S.), Roche Holding AG (Switzerland), Macrogen, Inc. (South Korea), and Eurofins Scientific (Luxembourg). The market is characterized by high competition and innovative product launches. Oxford Nanopore Technologies (U.K.) is a strong emerging market player with strong innovative solutions based on nanopore sequencing technology. For instance, in December 2016, Oxford Nanopore Technologies introduced its direct RNA sequencing kits to a small number of researchers. Additionally, in June 2014, F. Hoffmann-La Roche AG acquired Genia Technologies, Inc. (U.S.), to enhance its sequencing platform capabilities using nanopore technology. Next-Generation Sequencing (NGS) Market by Product (Hiseq, Miseq, Hiseq X Ten/X Five, NextSeq500, Ion Proton, PGM, Ions5, PacBio RSII), Services (Targeted, RNA, Exome, De Novo), & Application (Diagnostics, Biomarker, Agriculture) - Global Forecasts to  022 http://www.marketsandmarkets.com/Market-Reports/next-generation-sequencing-ngs-technologies-market-546.html MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets


News Article | May 25, 2017
Site: www.prnewswire.com

Willi-Food's operating divisions include Willi-Food, a distributor of a broad variety of kosher foods, and its wholly-owned Gold Frost, a designer, developer and distributor of branded kosher innovative dairy food products. Iram Graiver, President of Willi-Food, commented, "We are pleased with our first quarter 2017 results. We continue to place focus on ensuring sales of a more profitable product mix and our results reflect the success of this strategy. We have also recently invested additional efforts in our sales and marketing strategy in order to improve  consumer perception of our products within Israel, which will enable us to broaden our sales over the long-term. In addition, we look to expand our product lines and  increase market share while expanding into new markets. Combined with ongoing tight control over our corporate expenses, we expect 2017 to be a positive year for Willi-Food." Continued Mr. Graiver, "Our overall goal is to build a strong, stable and profitable company, with the aim of maximizing long-term value for our shareholders." Sales for the first quarter of 2017 increased by 0.8% to NIS 83.3 million (US$ 22.9 million) from NIS 82.6 million (US$ 22.7 million) recorded in the first quarter of 2016. Sales increased in the first quarter of 2017 primarily due to effective marketing campaign activities carried out in the first quarter and the Passover holiday, which occurred during the reporting period in the first quarter, while in 2016 the holiday occurred between the first and the second quarter. Gross profit for the first quarter of 2017 increased by 6% to NIS 22 million (US$ 6.1 million) compared to NIS 20.8 million (US$ 5.7 million) recorded in the first quarter of 2016. First quarter gross margin increased by 5.1% to 26.4% compared to gross margin of 25.1% for the same period in 2016. The increase in gross margin was the result of the Company's continued strategic focus on selling a favorable mix of products, which generate a higher gross margin. Willi-Food's operating income for the first quarter of 2017 decreased by 16.3% to NIS 6.7 million (US$ 1.8 million) compared to NIS 7.9 million (US$ 2.1 million) in the first quarter of 2016. Selling expenses increased by 31.5% from the comparable quarter of 2016 primarily due to a sharp increase in promotional expenses that included an approximately NIS 1.5 million (US$ 0.4 million) expense that was part of the annual budget approved by the Company's board of directors and related to a nationwide campaign which was launched in the second half of 2016 and continued in the first quarter 2017 aimed at broadening market awareness of Willi-Food's brands and products. Selling expenses as a percentage of sales were 14.2%, compared to 10.9% as in first quarter of 2016. General and administrative expenses were NIS 3.5 million (US$ 0.9 million) in the first quarter of 2017, a decrease of 6.6% compared to NIS 3.8 million (US$ 1.0 million) in first quarter of 2016. This was primarily due to a decrease of legal fees and a decrease in the measurable bonus paid to management. Willi-Food's income before taxes for the first quarter of 2017 was NIS 5.8 million (US$ 1.6 million) compared to income before taxes of NIS 6.3 million (US$ 1.7 million) recorded in the first quarter of 2015. Willi-Food's net profit in the first quarter of 2017 was NIS 4.3 million (US$ 1.2 million), or NIS 0.32 (US$ 0.09) per share, compared to NIS 4.7 million (US$ 1.3 million), or NIS 0.36 (US$ 0.10) per share, recorded in the first quarter of 2016. Willi-Food ended the first quarter of 2017 with NIS 192.9 million (US$ 53.1 million) in cash and securities net of short-term bank debt. Net cash to operating activities for 2017 first quarter was NIS 42.5 million (US$ 11.7 million). Willi-Food's shareholders' equity at the end of March 2017 was NIS 395.3 million (US$ 108.8 million). As previously announced, on May 21, 2017, the Company will host a conference call on Thursday, May 25, 2017 at 10am Eastern Time. To participate in the conference call, please call one of the following teleconferencing numbers. Please begin placing your calls at least 10 minutes before the conference call commences. If you are unable to connect using the toll-free numbers, try the international dial-in number. For those unable to participate, the teleconference will be available for replay on the company's website at http://willi-food.com/ beginning 24 hours after the call for a period of 30 days. As previously announced, on February 17, 2016, a search was conducted in the offices of the Company, the Parent Company, BSD Crown Ltd., and B.G.I Investments Ltd. (collectively, the "Group"), by the Israeli Securities Authority (the "ISA"), during which various documents and computers were taken from the Group's offices. A number of executives in the Group were investigated by the ISA, and Mr. Gregory Gurtovoy, member of the Company's board of directors and the indirect controlling shareholder, was detained for interrogation by the ISA for three days, after which, he was placed under house arrest for a period of two weeks (which has since ended), on the suspicion of the crimes of fraudulent acquisitions under aggravating circumstances, falsifying corporate documents, fraud, breach of fiduciary duty in a corporation, money laundering, as well as misleading reporting. To Company management's knowledge, the investigation by the ISA relates to an investment of approximately US$ 2.25 million (the "Investment") made during January 2016  in the form of bonds of a European company, which allegedly served as a collateral to a loan obtained by the controlling shareholder or another individual, and which was unrelated to the Company's operations. The Investment was carried out by B.H.W.F.I Ltd., a wholly owned subsidiary of the Company ("BHWFI"), pursuant to subscription forms to purchase 300 bonds with a nominal value of US$ 10,000 each ("Subscription Forms"). The Bonds bear an annual interest rate of 6%, payable semi-annually on June 30 and December 31 of each year as of the issue date until the final maturity date of 31 December 2018. The issuer has the right to repay the Bonds with prior notice of 30 days without penalty. On December 30, 2016, BHWFI and the issuer signed an agreement (the "Agreement") for an early redemption of the bonds for a total of US$ 1.8 million that was to be paid until February 15, 2017.  Similarly, as part of the terms of the Agreement, the issuer waived all its claims against BHWFI, including an alleged obligation to make an additional investment in bonds up to an aggregate amount of $5 million (as stated above, an amount of US$ 2.25 million was invested in the past). On March 21, 2017, a first payment in the amount of US$200 thousands was received. As of the financial results reporting date, due to uncertainty related to the collection of the remaining US$1.6 million debt, the company made non-cash provision in the amount of the unpaid debt. Note regarding our controlling shareholder, B.S.D. Crown Ltd. As previously announced, on May 8, 2017, Willi Food Investments Ltd. ("WIL"), reported announcements made by WIL's own controlling shareholder, B.S.D. Crown Ltd. (formerly known as Emblaze Ltd.) ("B.S.D."), and by BGI Investments (1961) Ltd. ("BGI"), a shareholder of BSD. B.S.D. announced the results of its extraordinary general meeting of shareholders with respect to the election of directors, among other things. BGI announced that the director nominees supported by BGI were not elected at the shareholders meeting of B.S.D., and as a result BGI does not have any representation on the board of directors of B.S.D.  BGI further announced that pursuant to a recent court ruling in Israel, it no longer sees itself as a controlling shareholder of B.S.D., and to the extent B.S.D. would have classified BGI as a non-controlling shareholder, the external directors supported by BGI would have been elected as director of B.S.D. BGI said it is studying the results of the shareholders meeting and it will reserve its rights. The Company also announced that, in furtherance of the announcement by BGI, the Company received a letter from Mr. Joseph Williger addressed to the Company and to WIL claiming that he is the controlling shareholder of B.S.D., and as a result, a controlling shareholder of WIL and the Company, commencing from the date of the shareholders meeting of B.S.D. On May 18, 2017, B.S.D. filed an urgent motion for relief against the Company, WIL and the directors serving in WIL, requesting that the Court order the convening of a meeting of the WIL's shareholders to replace the members of the WIL's Board of Directors, and instruct that this meeting be convened by June 11, 2017, in order to enable the new Board of Directors to be appointed to vote at the Company's shareholders' meeting scheduled for June 20, and immediately will change the control in WIL and the Company. The hearing on the request was set for May 29, 2017. On May 24, 2007, WIL and the Company filed their response, requesting the Court to outright reject B.S.D.'s motion and charging B.S.D. with the Company's and WIL's legal expenses in respect of the proceeding. The convenience translation of New Israeli Shekels (NIS) into U.S. dollars was made at the rate of exchange prevailing on March 31, 2017, U.S. $1.00 equals NIS 3.632 The translation was made solely for the convenience of the reader. The Company's consolidated financial results for the three-month period ended March 31, 2017 are presented in accordance with International Financial Reporting Standards ("IFRS"). G. Willi-Food International Ltd. (http://www.willi-food.com) is an Israeli-based company specializing in high-quality, great-tasting kosher food products. Willi-Food is engaged directly and through its subsidiaries in the design, import, marketing and distribution of over 600 food products worldwide. As one of Israel's leading food importers, Willi-Food markets and sells its food products to over 1,500 customers in Israel and around the world including large retail and private supermarket chains, wholesalers and institutional consumers. The company's operating divisions include Willi-Food in Israel and Gold Frost, a wholly owned subsidiary who designs, develops and distributes branded kosher, dairy-food products. This press release contains forward-looking statements within the meaning of safe harbor provisions of the Private Securities Litigation Reform Act of 1995 relating to future events or our future performance, such as statements regarding trends, demand for our products and expected sales, operating results, and earnings. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in those forward-looking statements. These risks and other factors include but are not limited to: monetary risks including changes in marketable securities or changes in currency exchange rates- especially the NIS/U.S. Dollar exchange rate, payment default by any of our major clients, the loss of one of more of our key personnel, changes in laws and regulations, including those relating to the food distribution industry, and inability to meet and maintain regulatory qualifications and approvals for our products, termination of arrangements with our suppliers, in particular Arla Foods, loss of one or more of our principal clients, increase or decrease in global purchase prices of food products, increasing levels of competition in Israel and other markets in which we do business, changes in economic conditions in Israel, including in particular economic conditions in the Company's core markets, our inability to accurately predict consumption of our products and changes in consumer preferences, our inability to protect our intellectual property rights, our inability to successfully integrate our recent acquisitions, insurance coverage not sufficient enough to cover losses of product liability claims and risks associated with product liability claims. We cannot guarantee future results, levels of activity, performance or achievements. The matters discussed in this press release also involve risks and uncertainties summarized under the heading "Risk Factors" in the Company's Annual Report on Form 20-F for the year ended December 31, 2016, filed with the Securities and Exchange Commission on April 27, 2017. These factors are updated from time to time through the filing of reports and registration statements with the Securities and Exchange Commission. We do not assume any obligation to update the forward-looking information contained in this press release. This information is intended to be reviewed in conjunction with the Company's filings with the Securities and Exchange Commission. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/g-willi-food-reports-first-quarter-2017-results-300463902.html


CNBG/BGI and the BTHNC have agreed to contribute genomic data collected from specimens of extracted pediatric brain tumor tissue, which will be uploaded into CAVATICA, a cloud-based platform developed by the CBTTC for collaboratively accessing, sharing and analyzing pediatric cancer data. In addition, BGI and CNBG will lead the recruitment of additional Chinese hospitals and will coordinate the execution of the CBTTC's protocols from sample collection to big data analysis and clinical treatment, for CBTTC member sites in China. "The new CBTTC member sites at Beijing Tiantan Hospital Neurosurgery Center and the China National GeneBank represent a giant leap forward in the collaborative, global effort to find cures and better treatments for pediatric cancer," said Adam Resnick, PhD, Scientific Chair of the CBTTC. "The China National GeneBank is proud to join CBTTC," said Xun Xu, Ph.D., Director of BGI Research and Executive Director of China National GeneBank. "We are looking forward to contributing our big data, genomic research capabilities and network of health care providers to advance the important work of the consortium in improving the outcomes and quality of life for pediatric brain cancer patients." BTHNC joins the CBTTC as the largest and most-renowned neurosurgical and center in China. Founded by Dr. Wang Chungcheng, a pioneer of neurosurgery in China in the early 1980s, Beijing Tiantan Hospital Neurosurgery Center provides a full range of adult and pediatric neurological surgery specialty services and performs more than 7,000 brain surgeries per year. About BGI and the China National GeneBank BGI was established in 1999 as Beijing Genomics Institute to participate in the original Human Genome Project. Since then, BGI has grown in to one of the world's largest genomics organizations, experienced in genomic research, commercial NGS services and sequencer manufacturing. BGI, now headquartered in Shenzhen, is committed to improving human health and enabling large-scale plant and animal genomics research by providing solutions for research, pharmaceutical, and clinical markets. Built and operated by BGI-Shenzhen, the China National GeneBank (CNGB) is the first national gene bank integrating a large-scale bio-repository and an omics database. It was established by the Chinese government, with the mission of collecting, preserving and exploiting genomics resources, and to build a network fostering global communication and collaboration on biodiversity conservation and genetic resources utilization. In addition, CNGB is supported by BGI's high-throughput sequencing and bio-informatics capacity, and it will not only provide a repository system for biological collection, but more importantly develop a novel platform to further understand genomic mechanisms of life. Visit www.bgi.com and www.cngb.org. About the Children's Brain Tumor Tissue Consortium The Children's Brain Tumor Tissue Consortium is a multi-institutional, collaborative research partnership dedicated to improving treatments and outcomes for children diagnosed with brain tumors.  The nucleus of the CBTTC is a state-of-the-art biorepository and informatics portal, which allows researchers from all over the world to access high-quality genomic and clinical tumor data. The CBTTC is currently composed of 15 member institutions from around the world. For more information, visit cbttc.org. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/childrens-brain-tumor-tissue-consortium-announces-addition-of-two-new-satellite-member-institutions-in-china-300454755.html


Led by large slot companies, report reveals $47.5 billion total impact, $17.9 billion direct impact, 55,000 direct employees and average direct annual wage of $89,400 LAS VEGAS, NV--(Marketwired - May 9, 2017) -  The global gaming supplier industry generated a total economic impact of $47.5 billion, supported more than 212,000 employees, including 55,000 direct employees, and paid a total of $14.2 billion in wages and salaries during 2016, according to a comprehensive report released today by the Association of Gaming Equipment Manufacturers (AGEM). The report titled "Industry Impact Analysis: Global Gaming Supplier 2017" was the result of an independent study commissioned by AGEM and conducted by the respected Las Vegas-based research firm Applied Analysis. The report (http://www.agem.org/images/news/AGEM_Industry_Impact_Analysis_17.pdf) is the most comprehensive review to date of the global gaming supplier industry that analyzes the size and scope of this technology-driven sector, specifically identifying AGEM members' global reach spanning every regulated gaming market in the world. With 151 member companies based in 23 countries, AGEM is anchored by the world's largest slot machine companies and AGEM Gold Members AGS, Ainsworth Game Technology, Aristocrat Technologies, Everi, International Game Technology (IGT), Konami Gaming, Merkur Gaming, NOVOMATIC Group, Scientific Games and Sega Sammy Creation. The AGEM membership also includes companies active in lotteries, systems, table games, online / interactive, mobile apps, game development, machine components and support products and services for the gaming industry. "A lot has changed in our sector during the past several years, but what hasn't changed is the impressive output of the global gaming suppliers and technology providers," said Marcus Prater, Executive Director of AGEM. "While there have been a variety of consolidation events at the very top in the past few years, the rise of the next level of manufacturers along with a general expansion of new products and technology created by supplier innovations have resulted in impressive growth and a strong overall impact." About the Association of Gaming Equipment Manufacturers (AGEM) AGEM is a non-profit international trade association representing manufacturers and suppliers of electronic gaming devices, lotteries, systems, table games, online technology, key components and support products and services for the gaming industry. AGEM works to further the interests of gaming equipment suppliers throughout the world. Through political action, regulatory influence, trade show partnerships, educational alliances, information dissemination and good corporate citizenship, the members of AGEM work together to create benefits for every company within the organization. Together, AGEM has assisted regulatory agencies and participated in the legislative process to solve problems and create a business environment where AGEM members can prosper while providing a strong level of support to education and responsible gaming initiatives. For more information, visit www.AGEM.org. About Applied Analysis and Methodology The 2017 edition of the Industry Impact Analysis: Global Gaming Supplier reports the annual economic impacts of the industry from 2013 to 2016. The latest report incorporates the most recent available information regarding the industry as whole and the companies operating within the market space. Applied Analysis utilized economic modeling techniques to quantify the ripple effect of the industry on the global economy. The current report is not necessarily comparable to prior editions due to a number of factors, including, but not limited to, technological advancements and the expansions of product offerings. Overall, the current research provides the most comprehensive reporting on the industry. Applied Analysis conducts a number of economic and gaming-related analyses. For more information, visit www.AppliedAnalysis.com. The current AGEM membership roster, 151 companies strong based in 23 countries, is a who's who of the supplier segment of the global gaming industry: AGEM Gold Members: AGS, Ainsworth Game Technology, Aristocrat Technologies, Everi, International Game Technology (IGT), Konami Gaming, Merkur Gaming, NOVOMATIC Group, Scientific Games and Sega Sammy Creation. AGEM Silver Members: Action Gaming, Aruze Gaming America, Casino Technology, Crane Payment Innovations (CPI), Gaming Partners International (GPI), JCM Global, NYX Gaming Group, Ortiz Gaming, Quixant PLC, Suzo-Happ Group, TCSJohnHuxley, William Hill US and Zitro. AGEM Bronze Members: Abbiati Casino Equipment, Alfastreet, Amatic Industries, APEX gaming, Astro Corp., BetConstruct, Bingotimes Digital Technology, Boss Gaming, Cammegh Limited, Century Gaming Technologies, CG Technology (CGT), Cole Kepro International, Euro Games Technology (EGT), Exacta Systems, FBM, Galaxy Gaming, Gamblit Gaming, GameCo, Gaming Arts, Gaming Support, Glory Global Solutions, Grand Vision Gaming, Incredible Technologies, Inspired Gaming, Interblock USA, Intervision Gaming, ISMS, Iverson Gaming Systems, Jumbo Technology, Matsui Gaming Machine Co., Metronia, Patriot Gaming & Electronics, Spintec, Table Trac, Vantiv Entertainment Solutions, Wells-Gardner Technologies and Win Systems. AGEM Associate Members: 3M Touch Systems, Adlink Technology, Advantech-Innocore, Agilysys, AMD, Arrow International, Asimex Global, Atrient, Automated Cashless Systems, AVUITY, Axiomtek, British Group Interactive (BGI), Camryn Industries, CardConnect, Carmanah Signs, Casino Connection International, Casino Screens, Catapult Global, CDC Gaming Reports, CMC Trading Engineering, Cooper Levenson, Digital Instinct, DiTronics Financial Services, Duane Morris LLP, EFCOtec Corporation, Eilers & Krejcik Gaming, Elite Gaming Technology, Esterline Interface Technologies, Fantini Research, Finnegan, Henderson, Farabow, Garrett & Dunner, Fox Rothschild, G2 Game Design, Gambling Compliance, GAN, Gaming and Entertainment Touch Technology, Gaming Capital Group, Ganlot, Gary Platt Manufacturing, Genesis Interactive Technologies, GeoComply USA, Global Gaming Group (G3), Greenberg Traurig, Holley, Driggs, Walch, Fine, Wray, Puzey & Thompson, House Advantage, Howard & Howard, Impact Display Solutions, Intel, IPS, James Industries, James Industry Research Group, JCS Technologies, Jones Walker, KEY-BAK, Kontron, Lazcano Sámano, Lewis Roca Rothgerber Christie, Lightstone Solutions, Majestic Realty, Media Resources, Metalcraft, NanoLumens, Olsen Gaming / Spectronix, Outpost Creative, Passport Technology, Patir Casino Seating, Portilla Ruy-Díaz y Aguilar, Proforma GPS, Regulatory Management Counselors (RMC), RMMC, RSM US LLP, SAP, SCA Gaming, Sightline Payments, Slot Constructor, Southwest Manufacturing Services, Spin Games, StylGame USA, Taft Stettinius & Hollister, Talent Associates, The Bright Group, Tohkoh Plastics America, Touch Dynamic, Touch Embedded Solutions, Tournament One, TOVIS, TraffGen USA, TransAct Technologies, Veridocs, Wells Fargo, Young Electric Sign Company (YESCO) and Zebra Technologies.

Loading BGI collaborators
Loading BGI collaborators